BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 249,388 shares, an increase of 49.2% from the December 15th total of 167,154 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average daily trading volume, of 117,346 shares, the short-interest ratio is presently 2.1 days. Based on an average daily trading volume, of 117,346 shares, the short-interest ratio is presently 2.1 days. Approximately 2.8% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research report on Monday, September 22nd. Zacks Research raised BioCardia to a “hold” rating in a report on Tuesday, September 23rd. Finally, Wall Street Zen upgraded BioCardia to a “sell” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

BioCardia Price Performance

BCDA stock remained flat at $1.40 during trading on Friday. 61,104 shares of the company’s stock traded hands, compared to its average volume of 91,305. BioCardia has a fifty-two week low of $1.00 and a fifty-two week high of $3.20. The firm has a market capitalization of $14.86 million, a PE ratio of -0.95 and a beta of 0.56. The firm has a 50 day simple moving average of $1.34 and a two-hundred day simple moving average of $1.63.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. As a group, analysts expect that BioCardia will post -3.52 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BioCardia stock. Cetera Investment Advisers purchased a new position in BioCardia, Inc. (NASDAQ:BCDA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned 0.37% of BioCardia as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.